M. A. Dagostino
P. G. Conaghan
C. Gaillez
M. Boers
E. Naredo
P. Carron
P. Hanova
T. Cazenave
G. Schett
Catholic University of Sacred Heart, UOC of Rheumatology, Agostino Gemelli University Polyclinic Foundation IRCCS, Roma, Italy
University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom
Novartis Pharma AG, Global Medical Affairs, Basel, Switzerland
Amsterdam Rheumatology and Immunology Centre, Amsterdam UMC, Vrije Universiteit, Department of Epidemiology and Data Science, Amsterdam, Netherlands
Hospital Fundación Jiménez Díaz and Autónoma University, Department of Rheumatology and Joint and Bone Research Unit, Madrid, Spain
VIB Inflammation Research Centre, Ghent University Hospital, Department of Rheumatology, Ghent, Belgium
1st Medical Faculty, Charles University, Institute of Rheumatologyand Department of Rheumatology, Prague, Czech Republic
Instituto de Rehabilitacion Psicofisica, Buenos Aires, Buenos Aires, Argentina
Salt lake Clinic, Intermountain Healthcare Medical Group, Salt lake city, United States of America
Novartis Ireland Limited, CTS Stats Analysis, Dublin, Iceland
Novartis Healthcare Pvt Ltd, Clinical Project Management, Hyderabad, India
Italy
United Kingdom
Switzerland
Netherlands
Spain
Belgium
Czech Republic
Argentina
United States
Iceland
India
Germany
N/A
Autoimmune (AI)
Musculoskeletal
Dermatology
Psoriatic arthritis
Psoriasis
N/A
secukinumab
N/A
Randomized
Placebo Control
Open Label
III
NCT02662985
Eli Lilly
N/A